S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Pulmonx Stock Price, News & Analysis (NASDAQ:LUNG)

$10.90
-0.13 (-1.18%)
(As of 11/30/2023 ET)
Compare
Today's Range
$10.81
▼
$11.15
50-Day Range
$7.89
▼
$11.09
52-Week Range
$5.30
▼
$14.27
Volume
416,209 shs
Average Volume
323,521 shs
Market Capitalization
$417.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.29
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Pulmonx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
21.9% Upside
$13.29 Price Target
Short Interest
Bearish
4.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Pulmonx in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$208,622 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.65) to ($1.62) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

865th out of 949 stocks

Surgical & Medical Instruments Industry

88th out of 94 stocks

See Top Rated MarketRank™ Stocks Here

LUNG stock logo

About Pulmonx Stock (NASDAQ:LUNG)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Stock Price History

LUNG Stock News Headlines

November 28, 2023 | americanbankingnews.com
Pulmonx Co. (NASDAQ:LUNG) Insider Sells $12,550.40 in Stock
November 21, 2023 | americanbankingnews.com
Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of "Moderate Buy" from Analysts
December 1, 2023 | Tomorrow Investor (Ad)
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
November 15, 2023 | finance.yahoo.com
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
October 31, 2023 | finance.yahoo.com
Pulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Call Transcript
October 30, 2023 | marketwatch.com
Pulmonx Shares Climb 17% as it Raises FY Guidance
October 30, 2023 | finance.yahoo.com
Pulmonx Corp (LUNG) Reports Record Q3 2023 Financial Results
October 30, 2023 | finance.yahoo.com
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
December 1, 2023 | Tomorrow Investor (Ad)
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
October 30, 2023 | finance.yahoo.com
Pulmonx Reports Record Third Quarter 2023 Financial Results
October 27, 2023 | benzinga.com
Pulmonx Earnings Preview
October 16, 2023 | finance.yahoo.com
Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023
October 11, 2023 | finanznachrichten.de
Pulmonx Corporation: Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
October 10, 2023 | finance.yahoo.com
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
October 5, 2023 | msn.com
Pulmonx (LUNG) Price Target Increased by 10.99% to 17.17
September 25, 2023 | abcnews.go.com
Iowa Gov. Kim Reynolds says her husband has lung cancer
September 6, 2023 | nasdaq.com
Craig-Hallum Initiates Coverage of Pulmonx (LUNG) with Buy Recommendation
September 5, 2023 | markets.businessinsider.com
Analysts’ Top Healthcare Picks: Pulmonx (LUNG), Omnicell (OMCL)
August 4, 2023 | msn.com
Piper Sandler Maintains Pulmonx (LUNG) Overweight Recommendation
August 3, 2023 | markets.businessinsider.com
Pulmonx (LUNG) Receives a Sell from Bank of America Securities
August 2, 2023 | finance.yahoo.com
Pulmonx Reports Second Quarter 2023 Financial Results
July 26, 2023 | finance.yahoo.com
Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference
July 17, 2023 | finance.yahoo.com
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
July 11, 2023 | msn.com
Citigroup Maintains Pulmonx (LUNG) Buy Recommendation
July 11, 2023 | benzinga.com
Citigroup Maintains Buy on Pulmonx, Raises Price Target to $16
July 10, 2023 | finance.yahoo.com
Shareholders in Pulmonx (NASDAQ:LUNG) are in the red if they invested a year ago
June 23, 2023 | msn.com
Pulmonx: Entry To Japan Market Bullish For Zephyr Volumes (Rating Upgrade)
See More Headlines
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUNG
CUSIP
N/A
CIK
1127537
Web
pulmonx.com
Phone
1-650-364-0400
Fax
N/A
Employees
269
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.29
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+21.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,920,000.00
Net Margins
-94.47%
Pretax Margin
-93.59%
Return on Equity
-43.93%
Return on Assets
-31.68%

Debt

Debt-to-Equity Ratio
0.30
Current Ratio
7.19
Quick Ratio
6.41

Sales & Book Value

Annual Sales
$53.66 million
Price / Sales
7.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.28 per share
Price / Book
3.32

Miscellaneous

Outstanding Shares
38,310,000
Free Float
36,124,000
Market Cap
$417.58 million
Optionable
Not Optionable
Beta
0.48
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














LUNG Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LUNG shares.
View LUNG analyst ratings or view top-rated stocks.

What is Pulmonx's stock price target for 2024?

7 equities research analysts have issued 12 month target prices for Pulmonx's shares. Their LUNG share price targets range from $8.00 to $18.00. On average, they predict the company's share price to reach $13.29 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts.

How have LUNG shares performed in 2023?

Pulmonx's stock was trading at $8.43 at the beginning of 2023. Since then, LUNG shares have increased by 29.3% and is now trading at $10.90.
View the best growth stocks for 2023 here.

When is Pulmonx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our LUNG earnings forecast.

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings data on Monday, October, 30th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06. The company had revenue of $17.67 million for the quarter, compared to analysts' expectations of $16.67 million. Pulmonx had a negative net margin of 94.47% and a negative trailing twelve-month return on equity of 43.93%. Pulmonx's revenue for the quarter was up 30.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) EPS.

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx updated its third quarter 2023 earnings guidance on Tuesday, October, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.60 million-$17.60 million, compared to the consensus revenue estimate of $16.31 million.

When did Pulmonx IPO?

(LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.42%), Morgan Stanley (5.79%), FMR LLC (5.30%), Deerfield Management Company L.P. Series C (2.66%), Braidwell LP (2.58%) and Victory Capital Management Inc. (2.50%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, Richard Ferrari and Scientific Corp Boston.
View institutional ownership trends.

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LUNG) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -